> top > docs > PMC:7200337 > spans > 51145-54099 > annotations

PMC:7200337 / 51145-54099 JSONTXT

Annnotations TAB JSON ListView MergeView

2_test

Id Subject Object Predicate Lexical cue
32505227-16299724-46575353 888-892 16299724 denotes 2006
32505227-26497532-46575354 1304-1308 26497532 denotes 2015
32505227-24885320-46575355 1674-1678 24885320 denotes 2014
32505227-32259480-46575357 2948-2952 32259480 denotes 2020
T99561 888-892 16299724 denotes 2006
T95047 1304-1308 26497532 denotes 2015
T7910 1674-1678 24885320 denotes 2014
T18004 2948-2952 32259480 denotes 2020

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T512 22-26 Body_part denotes Cell http://purl.org/sig/ont/fma/fma68646
T513 126-134 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T514 613-621 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T515 925-933 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T516 1003-1011 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T517 1117-1120 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T518 1191-1196 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T519 1211-1222 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T520 1227-1236 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T521 1282-1287 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T522 1376-1379 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T523 1408-1412 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T524 1454-1463 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T525 1468-1479 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T526 1487-1491 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T527 1525-1530 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T528 1623-1631 Body_part denotes monocyte http://purl.org/sig/ont/fma/fma62864
T529 1640-1651 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T530 1721-1729 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T531 2408-2416 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T532 2459-2473 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T533 2753-2761 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T54 1408-1412 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T55 1487-1491 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T56 1525-1530 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T325 145-153 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T326 728-736 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T327 1035-1038 Disease denotes ADE http://purl.obolibrary.org/obo/MONDO_0019383
T328 1322-1330 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T329 1402-1419 Disease denotes acute lung injury http://purl.obolibrary.org/obo/MONDO_0006502|http://purl.obolibrary.org/obo/MONDO_0015796
T331 1413-1419 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T332 1421-1424 Disease denotes ALI http://purl.obolibrary.org/obo/MONDO_0006502
T333 1557-1565 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T334 1590-1599 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T335 1603-1611 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T336 1681-1684 Disease denotes ADE http://purl.obolibrary.org/obo/MONDO_0019383
T337 1837-1840 Disease denotes ADE http://purl.obolibrary.org/obo/MONDO_0019383
T338 1884-1892 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T339 1977-1985 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T340 2102-2110 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T341 2165-2173 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T342 2345-2348 Disease denotes ADE http://purl.obolibrary.org/obo/MONDO_0019383
T343 2498-2501 Disease denotes ADE http://purl.obolibrary.org/obo/MONDO_0019383
T344 2523-2531 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T345 2675-2683 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T346 2686-2695 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T634 20-26 http://purl.obolibrary.org/obo/CL_0000236 denotes B Cell
T635 111-116 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T636 202-207 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T637 376-377 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T638 510-512 http://purl.obolibrary.org/obo/CLO_0001022 denotes Li
T639 510-512 http://purl.obolibrary.org/obo/CLO_0007314 denotes Li
T640 604-605 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T641 900-903 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T642 953-960 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T643 1102-1107 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T644 1141-1146 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T645 1162-1164 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T646 1191-1196 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T647 1227-1236 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T648 1262-1272 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T649 1282-1287 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T650 1311-1312 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T651 1342-1357 http://purl.obolibrary.org/obo/NCBITaxon_9544 denotes rhesus macaques
T652 1408-1412 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T653 1408-1412 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T654 1454-1463 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T655 1487-1491 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T656 1487-1491 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T657 1617-1622 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T658 1623-1631 http://purl.obolibrary.org/obo/CL_0000576 denotes monocyte
T659 1708-1709 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T660 1744-1745 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T661 2503-2506 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T662 2852-2854 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T58324 510-512 Chemical denotes Li http://purl.obolibrary.org/obo/CHEBI_30145
T89931 2784-2791 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T28 1402-1419 Phenotype denotes acute lung injury http://www.orpha.net/ORDO/Orphanet_178320
T29 1421-1424 Phenotype denotes ALI http://www.orpha.net/ORDO/Orphanet_178320

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1676 653-655 Gene denotes to Gene:6999
1677 142-144 Gene denotes to Gene:6999
1678 145-155 Species denotes SARS-CoV-2 Tax:2697049
1679 265-273 Species denotes patients Tax:9606
1702 1246-1248 Gene denotes to Gene:6999
1703 976-978 Gene denotes to Gene:6999
1704 944-946 Gene denotes to Gene:6999
1705 908-910 Gene denotes to Gene:6999
1706 843-845 Gene denotes to Gene:6999
1707 786-788 Gene denotes to Gene:6999
1708 728-736 Species denotes SARS-CoV Tax:694009
1709 825-833 Species denotes patients Tax:9606
1710 846-854 Species denotes patients Tax:9606
1711 1342-1357 Species denotes rhesus macaques Tax:9544
1712 1557-1565 Species denotes SARS-CoV Tax:694009
1713 1568-1576 Species denotes patients Tax:9606
1714 1603-1611 Species denotes SARS-CoV Tax:694009
1715 1617-1622 Species denotes human Tax:9606
1716 1746-1753 Species denotes patient Tax:9606
1717 1759-1767 Species denotes MERS-CoV Tax:1335626
1718 1863-1867 Species denotes rats Tax:10116
1719 1884-1894 Species denotes SARS-CoV-2 Tax:2697049
1720 1977-1987 Species denotes SARS-CoV-2 Tax:2697049
1721 1322-1341 Disease denotes SARS-CoV-1-infected MESH:C000657245
1722 1402-1419 Disease denotes acute lung injury MESH:D055371
1723 1590-1599 Disease denotes infection MESH:D007239
1735 2722-2724 Gene denotes to Gene:6999
1736 2636-2638 Gene denotes to Gene:6999
1737 2612-2614 Gene denotes to Gene:6999
1738 2236-2238 Gene denotes to Gene:6999
1739 2124-2126 Gene denotes to Gene:6999
1740 2102-2112 Species denotes SARS-CoV-2 Tax:2697049
1741 2366-2369 Species denotes CoV Tax:11118
1742 2532-2540 Species denotes patients Tax:9606
1743 2165-2173 Disease denotes COVID-19 MESH:C000657245
1744 2523-2531 Disease denotes COVID-19 MESH:C000657245
1745 2675-2695 Disease denotes SARS-CoV-2 infection MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T280 0-36 Sentence denotes Consequences of the B Cell Response:
T281 37-66 Sentence denotes Protection versus Enhancement
T282 67-346 Sentence denotes Several studies have demonstrated that high virus-specific antibody titers to SARS-CoV-2 are correlated with greater neutralization of virus in vitro and are inversely correlated with viral load in patients (Figure 4) (Okba et al., 2020, Wölfel et al., 2020, Zhao et al., 2020a).
T283 347-688 Sentence denotes Despite these indications of a successful neutralizing response in the majority of individuals, higher titers are also associated with more severe clinical cases (Li et al., 2020b, Okba et al., 2020, Zhao et al., 2020a, Zhou et al., 2020a), suggesting that a robust antibody response alone is insufficient to avoid severe disease (Figure 4).
T284 689-894 Sentence denotes This was also observed in the previous SARS-CoV-1 epidemic, where neutralizing titers were found to be significantly higher in deceased patients compared to patients who had recovered (Zhang et al., 2006).
T285 895-1051 Sentence denotes This has led to concerns that antibody responses to these viruses may contribute to pulmonary pathology via antibody-dependent enhancement (ADE) (Figure 4).
T286 1052-1310 Sentence denotes This phenomenon is observed when non-neutralizing virus-specific IgG facilitate entry of virus particles into Fc-receptor (FcR) expressing cells, particularly macrophages and monocytes, leading to inflammatory activation of these cells (Taylor et al., 2015).
T287 1311-1511 Sentence denotes A study in SARS-CoV-1-infected rhesus macaques found that anti-S IgG contributed to severe acute lung injury (ALI) and massive accumulation of monocytes and macrophages in the lung (Liu et al., 2019).
T288 1512-1680 Sentence denotes Furthermore, serum containing anti-S Ig from SARS-CoV-1 patients enhanced the infection of SARS-CoV-1 in human monocyte-derived macrophages in vitro (Yip et al., 2014).
T289 1681-1788 Sentence denotes ADE was also reported with a monoclonal antibody isolated from a patient with MERS-CoV (Wan et al., 2020c).
T290 1789-2026 Sentence denotes Somewhat reassuringly, there was no evidence of ADE mediated by sera from rats vaccinated with SARS-CoV-2 RBD in vitro (Quinlan et al., 2020) nor in macaques immunized with an inactivated SARS-CoV-2 vaccine candidate (Gao et al., 2020c).
T291 2027-2174 Sentence denotes As of now, there is no evidence that naturally developed antibodies toward SARS-CoV-2 contribute to the pathological features observed in COVID-19.
T292 2175-2301 Sentence denotes However, this possibility should be considered when it comes to experimental design and development of therapeutic strategies.
T293 2302-2436 Sentence denotes Importantly, in all of the descriptions of ADE as it relates to CoV, the FcR was necessary to trigger the antibody-mediated pathology.
T294 2437-2696 Sentence denotes High-dose intravenous immunoglobulin (IVIg), which may blunt ADE, has been trialed in COVID-19 patients (Cao et al., 2020b, Shao et al., 2020), but further studies are needed to determine the extent to which IVIg is safe or beneficial in SARS-CoV-2 infection.
T295 2697-2954 Sentence denotes Vaccine trials will need to consider the possibility of antibody-driven pathology upon antigen rechallenge; strategies using F(ab) fragments or engineered Fc monoclonal antibodies may prove particularly beneficial in this setting (Amanat and Krammer, 2020).